High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting
High-dose (HD) chemotherapy with melphalan and autologous blood stem cell transplantation (ABSCT) for treatment of symptomatic multiple myeloma (MM) on an outpatient basis has been well established in the USA and Canada, whereas in Germany and Western Europe an inpatient setting is the current stand...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
22 February 2017
|
| In: |
BMC cancer
Year: 2017, Jahrgang: 17 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-017-3137-4 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/s12885-017-3137-4 Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-017-3137-4 
|
| Verfasserangaben: | Katharina Lisenko, Sandra Sauer, Thomas Bruckner, Gerlinde Egerer, Hartmut Goldschmidt, Jens Hillengass, Johann W. Schmier, Sofia Shah, Mathias Witzens-Harig, Anthony D. Ho, Patrick Wuchter |
| Zusammenfassung: | High-dose (HD) chemotherapy with melphalan and autologous blood stem cell transplantation (ABSCT) for treatment of symptomatic multiple myeloma (MM) on an outpatient basis has been well established in the USA and Canada, whereas in Germany and Western Europe an inpatient setting is the current standard. We report on a German single-centre program to offer the procedure on an outpatient basis to selected patients. |
|---|---|
| Beschreibung: | Gesehen am 10.04.2018 |
| Beschreibung: | Online Resource |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-017-3137-4 |